What foods are labs allergic to

By Isabella Storyclaire

last updated November 21, 2024

Contributions sourced from

Common Allergies in Labs

Aug 15, 2019

Health & Safety

One thing we love about our pooches is how unique they are, no matter their breed, age, or gender your furry friend has their personality and habits. Another thing thats unique in dogs is their allergies some have severe reactions to different foods, and others react stronger to bacteria than others. Here are some of the most common allergies some canines may have or develop.

Fidos Food Allergies

There is an abundance of food items we eat every day that some pups are incredibly allergic to while others are not; here are a few.

The Most Common Food Allergies in Labs

Beef
Corn
Soy
Fish
Wheat
Chicken
Chicken Eggs

Dogs who are allergic to certain food products may become itchy, lose hair, get an ear infection, begin having overly-frequent potty breaks, and acquire skin infections after consuming that food.

How to Handle a Food Allergy in Your Lab

Figuring out what your food your dog is allergic to is the first step to relieving their allergy. Once you know what causes them irritation, you can start to purchase food that excludes their allergens or buy hypoallergenic formulas. When switching your pups food though, its important to slowly wean them off their old food as you transition into the new one to not give your canine an upset stomach.

Fur-ighteningFlea Allergies

Flea allergies are one of the most popular allergies vets treat in dogs. Fleas thrive in the summer and warmer months, so thats when you need to be the most cautious when it comes to Fidos health. Flea allergies will cause your pup to itch and itch and itch until their skin may turn rews, inflamed, and patchy. The most common places youll find flea bites are on the back and base of your pups tail.

How to Avoid and Treat Flea Allergies

Taking preventative measures is the best way to handle fleas.

Grooming your pup regularly can prevent an abundance of flea bites.
Keeping your floors swept and vacuumed regularly, along with any furniture will also help eliminate fleas from infesting your home and not only attacking your furry friend but you as well.
Also investing in flea medicine can help

If things do get out of control though you can always consult your vet for over the counter flea medicine or treatments.

Contact Allergies for Canines

Contact allergies are when your Lab develops a reaction to substances in the environment.

Common Contact Allergies in Labs

Dyes
Carpet deodorizes
Antibiotics
Rubber
Wool
Metals like nickel
Poison ivy sap
Salt used for icy roads

These allergies usually occur in areas of your pooch that have little to no fur, such as their paws, muzzle, and lower abdomen. If an irritable substance comes in contact with one of these areas youll notice it turning red and small bumps or blisters appearing.

Contact allergies are best determined by going to your vet and haveing an allergin test done on your Lab. Once you know what your furry friend is allergic to you can try to either use medication or remove/keep the substance away from your pup as much as possible. Hypoallergenic shampoo can also help if your pooch has severely sensitive skin.

Inhalant Allergies Thatll Irritate Your Pup

Inhalant allergies are the second most popular allergy in Labs and are caused by airborne or inhaled allergins.

The Most Common Inhalant Allergies in Your Lab

Dogs with inhalant allergies will usually scratch their legs, face, ears, groin, and armpit areas at an alarming amount. If this does occur, your vet will perform some tests on your pooch and either give them shots or a prescription drug to keep their symptoms at bay.

Bark-Worthy Bacterial Allergies

Bacterial allergies occur due to the reactions all of these other allergins create. Due to skin irritation and hair loss, your Lab can develop lesions. If this happens, your vet will probably prescribe a topical cream or spray to treat the infected area.

Just like us, dogs have numerous allergies the best way to deal with them is to be observant, notice when something is off with your dog, and bring it up with your vet so your Lab can stay happy and healthy.

Labrador Retriever Allergies: How to Spot the Signs and Symptoms

Labrador Retrievers are one of the most popular dog breeds in the world, beloved for their friendly personalities, loyalty, and intelligence. However, like many breeds, Labradors are prone to allergies that can cause discomfort and distress. As a pet owner, its important to understand the signs and symptoms of allergies in Labradors so you can provide the best care for your furry friend. In this blog post, well discuss the common signs of allergies in Labradors, and provide tips on how to manage and treat this condition to keep your dog happy and healthy.

Labrador Retrievers are friendly, loyal dogs that are beloved by many families. However, like any other breed, they are susceptible to allergies. Allergies can cause a lot of discomfort for your furry friend, so its important to know what to look for. In this blog post, well discuss the signs and symptoms of Labrador Retriever allergies and what you can do to help your pup feel better.

1. Common Allergies in Labrador Retrievers

The first step in identifying allergies in your Labrador Retriever is to know what the common allergens are. Some common allergens that affect Labradors are:

Food: Your dog may be allergic to certain ingredients in their food, such as chicken, beef, or grains. Environmental: Pollen, dust, and mold can cause allergies in dogs. Parasites: Fleas, ticks, and mites can cause allergic reactions in your dog. Contact: Your dog can be allergic to things they come into contact with, such as certain fabrics or cleaning products.

2. Signs and Symptoms of Labrador Retriever Allergies

Once you know what the common allergens are, you need to know what to look for. Here are some signs and symptoms of allergies in Labrador Retrievers:

Itching: One of the most common signs of allergies in dogs is itching. Your dog may scratch, lick, or bite their skin excessively. Redness: Allergies can cause your dogs skin to become red and inflamed. Hot Spots: Hot spots are areas of skin that are inflamed and irritated. They can be caused by allergies and can be painful for your dog. Ear Infections: Allergies can cause your dogs ears to become infected. Signs of an ear infection include shaking their head, scratching their ears, and a bad odor coming from their ears. Digestive Issues: Allergies can cause digestive issues such as diarrhea, vomiting, and gas.

3. How to Help Your Labrador Retriever with Allergies

If you suspect that your Labrador Retriever has allergies, there are several things you can do to help them feel better:

Visit your vet: Your vet can help you determine what your dog is allergic to and recommend treatment options. Change their diet: If your dog is allergic to certain ingredients in their food, you may need to switch to a different food. Keep your home clean: Regularly cleaning your home can help reduce your dogs exposure to allergens such as dust and mold. Use allergy medication: Your vet may recommend allergy medication to help relieve your dogs symptoms. Use flea and tick prevention: Fleas, ticks, and mites can cause allergies in dogs, so using flea and tick prevention can help reduce the risk.

allergies can be a real problem for Labrador Retrievers, but with the right care and attention, you can help your furry friend feel better. By knowing the signs and symptoms of allergies, you can identify them early and take the necessary steps to provide relief. Remember to always consult with your vet if you suspect your dog has allergies.

In conclusion, its important to keep an eye out for any unusual symptoms in your Labrador Retriever. If you suspect that your furry friend may be suffering from allergies, take action immediately. With proper care and treatment, you can help your dog feel more comfortable and happy. Always remember to consult with your veterinarian for the best course of action. By being proactive and attentive, you can ensure that your Labrador Retriever lives a healthy and happy life free from allergies.

Antibody reduces allergic reactions to multiple foods in NIH clinical trial

News Release

Sunday, February 25, 2024

Antibody reduces allergic reactions to multiple foods in NIH clinical trial

Drug can help protect kids with multiple food allergies during accidental exposure.

A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction in a late-stage clinical trial. Nearly 67% of participants who completed the antibody treatment could consume a single dose of 600 milligrams (mg) or more of peanut protein, equivalent to 2.5 peanuts, without a moderate or severe allergic reaction, in contrast with less than 7% of participants who received placebo. The treatment yielded similar outcomes for egg, milk, wheat, cashew, walnut and hazelnut at a threshold dose of 1,000 mg protein or more. This suggests the antibody therapy has the potential to protect children and adolescents if they accidentally eat a food to which they are allergic despite efforts to avoid it, according to the investigators. The findings were presented today at the American Academy of Allergy, Asthma & Immunology Annual Meeting in Washington, D.C., and published in The New England Journal of Medicine.

People with food allergies and their caregivers need to maintain constant vigilance to avoid foods that could cause a potentially life-threatening allergic reaction. This is extremely stressful, especially for parents of young children, said Jeanne Marrazzo, M.D., M.P.H., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health and the trials regulatory sponsor. Although food avoidance remains critical, the findings reported today show that a medicine can help reduce the risk of allergic reactions to common foods and may provide protection from accidental exposure emergencies.

NIAID funds the ongoing trial with additional support from and collaboration with Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation. The two companies collaborate to develop and promote omalizumab, marketed as Xolair, and are supplying it for the trial. The National Center for Advancing Translational Sciences, also part of NIH, supports some of the staff, space and services used to conduct the trial.

An estimated 7.6% of children in the United State roughly 5.5 million kids have food allergies. On February 16, 2024, the Food and Drug Administration approved omalizumab for the reduction of allergic reactions, including anaphylaxis, that may occur with an accidental exposure to one or more foods in adults and children aged 1 year and older with food allergy. The FDA approval was based on data from a planned interim analysis of the Phase 3 NIAID trial. People taking omalizumab still need to avoid foods they are allergic to. Omalizumab is not approved for the emergency treatment of allergic reactions, including anaphylaxis.

Previously, the only available treatment for food allergy was oral immunotherapy, or OIT, which involves daily ingestion of a specific food allergen in gradually increasing doses up to a maintenance amount.

The multi-stage trial is called Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults, or OUtMATCH. The first stage of the study was designed to see if taking omalizumab increased the threshold for the amount of food that caused allergic reactions, thereby reducing the likelihood of reactions to small amounts of food allergens during accidental exposure.

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions. This renders these cells much less sensitive to stimulation by any allergen.

The NIAID-funded Consortium for Food Allergy Research (CoFAR) is conducting OUtMATCH at 10 locations across the United States. The CoFAR has enrolled 177 children and adolescents ages 1 to 17 years and three adults ages 18 to 55 years, all with confirmed allergy to peanut and at least two other common foods among milk, egg, cashew, wheat, hazelnut or walnut.

In the first stage of the trial, people who reacted to small amounts of food allergens during oral food challenges were assigned at random to receive injections of either omalizumab or placebo. Neither the participants nor the investigators knew which food was used in a challenge nor who was in which group. After 16 to 20 weeks of injections, the participants were challenged again in a carefully controlled setting to see if they could tolerate a greater amount of food than they did at the outset. The goal was to find out if omalizumab injections led to a statistically significant increase in the proportion of participants who could consume roughly the equivalent of 2.5 peanuts without a moderate or severe allergic reaction, up from less than half a peanut at the outset, and similarly greater quantities of milk, egg or cashew among people allergic to those foods.

Investigators found that omalizumab was superior to placebo in increasing the reaction threshold for peanut, milk, egg and cashew as well as wheat, walnut and hazelnut to levels that likely would protect against allergic reactions upon accidental exposure. Seventy-nine of 118 omalizumab-treated children and adolescents, or 66.9%, could consume at least a single dose of 600 mg or more of peanut protein without a moderate or severe allergic reaction during the post-treatment challenge, in contrast with four out of 59 children and adolescents, or 6.8%, who received placebo. The researchers observed similar results for milk, egg, cashew, wheat, walnut and hazelnut at a threshold dose of 1,000 mg protein or more.

Many omalizumab-treated participants ate more than 600 mg of peanut protein without a moderate or severe allergic reaction. Sixty-seven percent consumed a cumulative dose of 1,044 mg of peanut protein, or about four peanuts, and 44% ate a cumulative dose of 6,044 mg of peanut protein, or about 25 peanuts. In addition, substantial proportions of treated participants consumed a cumulative dose of 1,044 mg of more than one food without a moderate or severe allergic reaction. Sixty-nine percent ate this amount of two foods, and 47%, three foods.

The first 60 participants who completed the first stage entered a 24-week open-label extension of omalizumab injections followed by additional oral food challenges. Most participants who had received omalizumab in the first stage maintained or increased the amount of food protein they could consume without an allergic reaction during the extension.

Robert Wood, M.D., and Sharon Chinthrajah, M.D. are leading the trial. Dr. Wood is the Julie and Neil Reinhard Professor of Pediatric Allergy and Immunology and director of the Pediatric Clinical Research Unit at the Johns Hopkins University School of Medicine. Dr. Chinthrajah is an associate professor of medicine and of pediatric allergy and clinical immunology at Stanford University School of Medicine.

Further information about the ongoing OUtMATCH trial is available at ClinicalTrials.gov under study identifier NCT03881696. The outcomes of later stages of the trial will be published in the future.

NIAID conducts and supports researchat NIH, throughout the United States, and worldwideto study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIHTurning Discovery Into Health